# A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07535437/  
OnCo record `nct07535437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ivonescimab, datopotamab deruxtecan and osimertinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535437 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 66 participants, started 2026-04-09 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Dato-DXd; Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: determine the maximum tolerated dose (MTD) (phase I); progression free survival (phase I); measure objective response rate (ORR) (phase II). Lung eligibility wording from the registry: "* Biopsy-proven metastatic non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07535437
- Phase: 1/2
- Setting: A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT07535437: https://clinicaltrials.gov/study/NCT07535437

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07535437.json